Home The Word Brain My Amedeo FAQ Privacy About Flying Publisher   

The Angels Initiative

Stroke prevention

  Prostate Cancer

  Free Subscription

Articles published in Prostate

Retrieve available abstracts of 321 articles:
HTML format

Single Articles

    May 2023
  1. SEMSARIAN CR, Ma T, Nickel B, Barratt A, et al
    Low-risk prostate lesions: An evidence review to inform discussion on losing the "cancer" label.
    Prostate. 2023;83:498-515.
    PubMed     Abstract available

  2. WERNER RA, Habacha B, Lutje S, Bundschuh L, et al
    Lack of repeatability of radiomic features derived from PET scans: Results from a (18) F-DCFPyL test-retest cohort.
    Prostate. 2023;83:547-554.
    PubMed     Abstract available

    April 2023
  3. LU JG, Lo ET, Williams C, Ma B, et al
    Expression of high molecular weight cytokeratin-A novel feature of aggressive and innate hormone-refractory prostatic adenocarcinoma.
    Prostate. 2023;83:462-469.
    PubMed     Abstract available

    March 2023
  4. MAFFEI D, Fasulo V, Avolio PP, Saitta C, et al
    Diagnostic performance of Micro-Ultrasound at MRI-guided confirmatory biopsy in patients under active surveillance for low-risk prostate cancer.
    Prostate. 2023 Mar 24. doi: 10.1002/pros.24532.
    PubMed     Abstract available

  5. STANGL-KREMSER J, Ricaurte-Fajardo A, Subramanian K, Osborne JR, et al
    Response to RL-225Ac in prostate cancer: effect of prior treatment with RL-177Lu: a systematic review of the literature.
    Prostate. 2023 Mar 24. doi: 10.1002/pros.24531.
    PubMed     Abstract available

  6. OERTHER B, Engel H, Nedelcu A, Schlett CL, et al
    Prediction of upgrade to clinically significant prostate cancer in patients under active surveillance: performance of a fully automated AI-algorithm for lesion detection and classification.
    Prostate. 2023 Mar 23. doi: 10.1002/pros.24528.
    PubMed     Abstract available

  7. CAPUTO SA, Hawkins M, Jaeger EB, Fleming W, et al
    Clinical and Molecular Determinants of PSA Response to Bipolar Androgen Therapy in Prostate Cancer.
    Prostate. 2023 Mar 23. doi: 10.1002/pros.24529.
    PubMed     Abstract available

  8. HASAN S, Lazarev S, Garg M, Gozland R, et al
    Proton therapy for high-risk prostate cancer: Results from the Proton Collaborative Group PCG 001-09 prospective registry trial.
    Prostate. 2023 Mar 22. doi: 10.1002/pros.24525.
    PubMed     Abstract available

  9. WONG CHM, Xu N, Lim J, Feng KK, et al
    Adverse metabolic consequences of androgen deprivation therapy (ADT) on Asian patients with prostate cancer: Primary results from the real-life experience of ADT in Asia (READT) study.
    Prostate. 2023 Mar 20. doi: 10.1002/pros.24519.
    PubMed     Abstract available

  10. ROBECK P, Xu L, Ahmed D, Dragomir A, et al
    P-score in preoperative biopsies accurately predicts P-score in final pathology at radical prostatectomy in patients with localized prostate cancer.
    Prostate. 2023 Mar 20. doi: 10.1002/pros.24523.
    PubMed     Abstract available

  11. LEWIS AR, Costello BA, Quevedo F, Pagliaro LC, et al
    Dynamic assessment of serum chromogranin A and treatment response with abiraterone acetate in metastatic castration-resistant prostate cancer.
    Prostate. 2023 Mar 16. doi: 10.1002/pros.24498.
    PubMed     Abstract available

  12. TELLI T, Tuncel M, Karabulut E, Aksoy S, et al
    Prognostic factors of overall and prostate-specific antigen-progression-free survival in metastatic castration-resistant prostate cancer patients treated with (177) Lu-PSMA-617. A single-center prospective observational study.
    Prostate. 2023 Mar 15. doi: 10.1002/pros.24518.
    PubMed     Abstract available

  13. CHIERIGO F, Flammia RS, Sorce G, Hoeh B, et al
    The association of type and number of high-risk criteria with cancer specific mortality in prostate cancer patients treated with radiotherapy.
    Prostate. 2023 Mar 15. doi: 10.1002/pros.24505.
    PubMed     Abstract available

  14. TAN YG, Law YM, Ngo NT, Khor LY, et al
    Patient-reported functional outcomes and oncological control after primary focal cryotherapy for clinically significant prostate cancer: A Phase II mandatory biopsy-monitored study.
    Prostate. 2023 Mar 9. doi: 10.1002/pros.24517.
    PubMed     Abstract available

  15. CHAMORRO CASTILLO L, Garcia Morales L, Ruiz Lopez D, Salguero Segura J, et al
    The role of multiparametric magnetic resonance in active surveillance of a low-risk prostate cancer cohort from clinical practice.
    Prostate. 2023 Mar 9. doi: 10.1002/pros.24515.
    PubMed     Abstract available

  16. CONOVER MM, Weaver J, Fan B, Leitz G, et al
    Cardiovascular outcomes among patients with castration-resistant prostate cancer: A comparative safety study using US administrative claims data.
    Prostate. 2023 Mar 6. doi: 10.1002/pros.24510.
    PubMed     Abstract available

  17. STINSON J, McCall C, Dobbs RW, Mistry N, et al
    Vitamin D and genetic ancestry are associated with apoptosis rates in benign and malignant prostatic epithelium.
    Prostate. 2023;83:352-363.
    PubMed     Abstract available

  18. REN J, Melamed J, Taneja SS, Wysock JS, et al
    Prostate magnetic resonance imaging-targeted biopsy global grade correlates better than highest grade with prostatectomy grade.
    Prostate. 2023;83:323-330.
    PubMed     Abstract available

    February 2023
  19. BECK J, Rouleau M, Lemire F, Neveu B, et al
    Mass spectrometry redefines optimal testosterone thresholds in prostate cancer patients undergoing androgen deprivation therapy.
    Prostate. 2023 Feb 27. doi: 10.1002/pros.24501.
    PubMed     Abstract available

  20. ZHUANG Q, Huang S, Li Z
    Prospective role of 3betaHSD1 in prostate cancer precision medicine.
    Prostate. 2023 Feb 26. doi: 10.1002/pros.24504.
    PubMed     Abstract available

  21. OYENUGA M, Halabi S, Oyenuga A, McSweeney S, et al
    Quality of life outcomes for patients with metastatic castration-resistant prostate cancer and pretreatment prognostic score.
    Prostate. 2023 Feb 26. doi: 10.1002/pros.24503.
    PubMed     Abstract available

  22. LEE J, Wickes BL, Fu J, Brockman NE, et al
    Prevalence of genotoxic bacteria in men undergoing biopsy for prostate cancer.
    Prostate. 2023 Feb 26. doi: 10.1002/pros.24500.
    PubMed     Abstract available

  23. TIRUYE T, O'Callaghan M, Ettridge K, Jay A, et al
    Factors impacting on sexual function among men on active surveillance for prostate cancer.
    Prostate. 2023 Feb 24. doi: 10.1002/pros.24502.
    PubMed     Abstract available

  24. ADAMS MN, Croft LV, Urquhart A, Saleem MAM, et al
    hSSB1 (NABP2/OBFC2B) modulates the DNA damage and androgen-induced transcriptional response in prostate cancer.
    Prostate. 2023 Feb 22. doi: 10.1002/pros.24496.
    PubMed     Abstract available

  25. CHEN LC, Huang SP, Shih CT, Li CY, et al
    ATP8B1: A prognostic prostate cancer biomarker identified via genetic analysis.
    Prostate. 2023 Feb 15. doi: 10.1002/pros.24495.
    PubMed     Abstract available

  26. GRAHAM LS, Haffner MC, Sayar E, Gawne A, et al
    Clinical, pathologic, and molecular features of amphicrine prostate cancer.
    Prostate. 2023 Feb 13. doi: 10.1002/pros.24497.
    PubMed     Abstract available

  27. TAKESHITA N, Sakamoto S, Yamada Y, Sazuka T, et al
    Detection of intraductal carcinoma in prostate cancer patients with small tumor volume.
    Prostate. 2023 Feb 10. doi: 10.1002/pros.24492.
    PubMed     Abstract available

  28. KARTHIKEYAN SK, Xu N, Ferguson Rd JE, Rais-Bahrami S, et al
    Identification of androgen response-related lncRNAs in prostate cancer.
    Prostate. 2023 Feb 9. doi: 10.1002/pros.24494.
    PubMed     Abstract available

    January 2023
  29. BRAY G, Bahadori A, Rama D
    Salvage stereotactic body radiation therapy for locally recurrent prostate cancer following primary radiation therapy, are benefits worth toxicity risks?: A systematic review.
    Prostate. 2023 Jan 30. doi: 10.1002/pros.24491.
    PubMed     Abstract available

  30. RAM P, Mandal S, K Das M, Nayak P, et al
    The impact of genetic aberrations on response to radium-223 treatment for castration-resistant prostate cancer with bone metastases.
    Prostate. 2023 Jan 30. doi: 10.1002/pros.24489.

  31. DIAMAND R, Peltier A, Roche JB, Lievore E, et al
    Risk stratification for early biochemical recurrence of prostate cancer in the era of multiparametric magnetic resonance imagining-targeted biopsy.
    Prostate. 2023 Jan 27. doi: 10.1002/pros.24490.
    PubMed     Abstract available

  32. YANAGISAWA T, Hata K, Narita S, Hatakeyama S, et al
    Docetaxel versus abiraterone for metastatic hormone-sensitive prostate cancer with focus on efficacy of sequential therapy.
    Prostate. 2023 Jan 20. doi: 10.1002/pros.24488.
    PubMed     Abstract available

  33. RAM P, Nayak P, Mandal S, Das MK, et al
    Holmium laser enucleation of the prostate in men on active surveillance for prostate cancer with refractory lower urinary tract symptoms secondary to enlarged prostates.
    Prostate. 2023 Jan 19. doi: 10.1002/pros.24487.

  34. DAVIDSSON S, Messing Eriksson A, Udumyan R, Swanholm P, et al
    Androgen deprivation therapy in men with prostate cancer is not associated with COVID-2019 infection.
    Prostate. 2023 Jan 19. doi: 10.1002/pros.24485.
    PubMed     Abstract available

  35. STANGL A, Wilner C, Li P, Maahs L, et al
    Molecular features and race-associated outcomes of SPOP-mutant metastatic castration-resistant prostate cancer.
    Prostate. 2023 Jan 5. doi: 10.1002/pros.24481.
    PubMed     Abstract available

  36. MAVURA Y, Song H, Xie J, Tamayo P, et al
    Transcriptomic profiling and genomic rearrangement landscape of Nigerian prostate cancer.
    Prostate. 2023 Jan 4. doi: 10.1002/pros.24471.
    PubMed     Abstract available

  37. BHAT TA, Dheeraj A, Nambiar DK, Singh SP, et al
    Decursin inhibits EGFR-ERK1/2 signaling axis in advanced human prostate carcinoma cells.
    Prostate. 2023 Jan 3. doi: 10.1002/pros.24482.
    PubMed     Abstract available

  38. AGUIAR JA, Li EV, Siddiqui MR, Soliman MA, et al
    Utilization of genetic testing in men with advanced prostate cancer.
    Prostate. 2023 Jan 2. doi: 10.1002/pros.24480.
    PubMed     Abstract available

  39. BRODOWSKY EC, Sood A, Butaney M, Majdalany SE, et al
    Time to second biochemical recurrence as a prognostic indicator in postprostatectomy patients who undergo salvage radiation therapy: An RTOG 9601 based post hoc analysis.
    Prostate. 2023;83:64-70.
    PubMed     Abstract available

    December 2022
  40. CHANG T, Lian Z, Ma S, Liang Z, et al
    Combination with vorinostat enhances the antitumor activity of cisplatin in castration-resistant prostate cancer by inhibiting DNA damage repair pathway and detoxification of GSH.
    Prostate. 2022 Dec 28. doi: 10.1002/pros.24479.
    PubMed     Abstract available

  41. WEI J, Beebe-Dimmer J, Shi Z, Sample C, et al
    Association of rare, recurrent nonsynonymous variants in the germline of prostate cancer patients of African ancestry.
    Prostate. 2022 Dec 25. doi: 10.1002/pros.24477.
    PubMed     Abstract available

  42. RAJWA P, Pfister D, Rieger C, Heidenreich J, et al
    Importance of magnetic resonance imaging and prostate-specific membrane antigen PET-CT in patients treated with salvage radical prostatectomy for radiorecurrent prostate cancer.
    Prostate. 2022 Dec 23. doi: 10.1002/pros.24470.
    PubMed     Abstract available

  43. FERNANDEZ-PEREZ MP, Perez-Navarro E, Alonso-Gordoa T, Conteduca V, et al
    A correlative biomarker study and integrative prognostic model in chemotherapy-naive metastatic castration-resistant prostate cancer treated with enzalutamide.
    Prostate. 2022 Dec 23:e24469. doi: 10.1002/pros.24469.
    PubMed     Abstract available

  44. UNTERBERGER CJ, McIlwain SJ, Tsourkas PK, Maklakova VI, et al
    Conditional gene regulation models demonstrate a pro-proliferative role for growth hormone receptor in prostate cancer.
    Prostate. 2022 Dec 22. doi: 10.1002/pros.24474.
    PubMed     Abstract available

  45. ROSSETTO I, Santos F, Kido L, Lamas C, et al
    Tempol differential effect on prostate cancer inflammation: In vitro and in vivo evaluation.
    Prostate. 2022 Dec 22. doi: 10.1002/pros.24473.
    PubMed     Abstract available

  46. YANG J, Tang Y, Zhou C, Zhou M, et al
    The use of (68) Ga-PSMA PET/CT to stratify patients with PI-RADS 3 lesions according to clinically significant prostate cancer risk.
    Prostate. 2022 Dec 21. doi: 10.1002/pros.24475.
    PubMed     Abstract available

  47. XU Y, Xu M, Li X, Weng X, et al
    SOX9 and HMGB3 co-operatively transactivate NANOG and promote prostate cancer progression.
    Prostate. 2022 Dec 21. doi: 10.1002/pros.24476.
    PubMed     Abstract available

  48. JURACEK J, Madrzyk M, Stanik M, Ruckova M, et al
    A tissue miRNA expression pattern is associated with disease aggressiveness of localized prostate cancer.
    Prostate. 2022 Dec 8. doi: 10.1002/pros.24466.
    PubMed     Abstract available

  49. SASAKI T, Yoshikawa Y, Kageyama T, Sugino Y, et al
    Prostate fibroblasts enhance androgen receptor splice variant 7 expression in prostate cancer cells.
    Prostate. 2022 Dec 7. doi: 10.1002/pros.24468.
    PubMed     Abstract available

  50. KAZAN O, Gunduz N, Kir G, Iplikci A, et al
    The cribriform morphology impairs Gleason 7 prostate cancer lesion detection on multiparametric magnetic resonance imaging.
    Prostate. 2022 Dec 7. doi: 10.1002/pros.24465.
    PubMed     Abstract available

  51. AMARO GM, da Silva ADT, Tamarindo GH, Lamas CA, et al
    Differential effects of omega-3 PUFAS on tumor progression at early and advanced stages in TRAMP mice.
    Prostate. 2022;82:1491-1504.
    PubMed     Abstract available

  52. DENMEADE S, Lim SJ, Isaaccson Velho P, Wang H, et al
    PSA provocation by bipolar androgen therapy may predict duration of response to first-line androgen deprivation: Updated results from the BATMAN study.
    Prostate. 2022;82:1529-1536.
    PubMed     Abstract available

    November 2022
  53. MIYAHIRA AK, Hawley JE, Adelaiye-Ogala R, Calais J, et al
    Exploring new frontiers in prostate cancer research: Report from the 2022 Coffey-Holden prostate cancer academy meeting.
    Prostate. 2022 Nov 28. doi: 10.1002/pros.24461.
    PubMed     Abstract available

  54. NAITO Y, Kato M, Kawanishi H, Yamamoto A, et al
    Clinical utility of intraductal carcinoma of the prostate in treatment selection for metastatic hormone-sensitive prostate cancer.
    Prostate. 2022 Nov 24. doi: 10.1002/pros.24462.
    PubMed     Abstract available

  55. SU CT, Nizialek E, Berchuck JE, Vlachostergios PJ, et al
    Differential responses to taxanes and PARP inhibitors in ATM- versus BRCA2-mutated metastatic castrate-resistant prostate cancer.
    Prostate. 2022 Nov 16. doi: 10.1002/pros.24454.
    PubMed     Abstract available

  56. ALASKAR A, Abdulraqeb Ali A, Hassan S, Shinwari Z, et al
    Inhibition of signaling downstream of beta-2 adrenoceptor by propranolol in prostate cancer cells.
    Prostate. 2022 Nov 14. doi: 10.1002/pros.24455.
    PubMed     Abstract available

  57. TRABZONLU L, Pienta KJ, Trock BJ, De Marzo AM, et al
    Presence of cells in the polyaneuploid cancer cell (PACC) state predicts the risk of recurrence in prostate cancer.
    Prostate. 2022 Nov 13. doi: 10.1002/pros.24459.
    PubMed     Abstract available

  58. PANUNZIO A, Sorce G, Hoeh B, Hohenhorst L, et al
    Effect of positive surgical margins at radical prostatectomy on cancer-specific mortality in high/very high-risk prostate cancer patients with Gleason Grade Group 4-5.
    Prostate. 2022 Nov 6. doi: 10.1002/pros.24458.
    PubMed     Abstract available

  59. NYGARD LH, Talala K, Taari K, Tammela TLJ, et al
    Antidiabetic drugs, glycemic control and risk of benign prostatic hyperplasia.
    Prostate. 2022 Nov 3. doi: 10.1002/pros.24456.
    PubMed     Abstract available

  60. CHAN JSK, Tang P, Hui JMH, Lee YHA, et al
    Association between duration of gonadotrophin-releasing hormone agonist use and cardiovascular risks: A population-based competing-risk analysis.
    Prostate. 2022;82:1477-1480.
    PubMed     Abstract available

  61. BROWN NE, Jones A, Hunt BG, Waltz SE, et al
    Prostate tumor RON receptor signaling mediates macrophage recruitment to drive androgen deprivation therapy resistance through Gas6-mediated Axl and RON signaling.
    Prostate. 2022;82:1422-1437.
    PubMed     Abstract available

    October 2022
  62. LEE EE, Singh T, Hu C, Han M, et al
    The impact of salvage radiotherapy initiation at PSA
    Prostate. 2022 Oct 31. doi: 10.1002/pros.24452.
    PubMed     Abstract available

  63. OISHI T, Hatakeyama S, Tabata R, Fujimori D, et al
    Effects of apalutamide dose reduction on skin-related adverse events in patients with advanced prostate cancer: A multicenter retrospective study.
    Prostate. 2022 Oct 31. doi: 10.1002/pros.24453.
    PubMed     Abstract available

  64. NIU S, Liu Y, Ding X, Xu Y, et al
    (18) F-DCFPyL positron emission tomography/magnetic resonance imaging-guided ultrasound fusion biopsy is an identical pathway in prostate cancer diagnosis.
    Prostate. 2022 Oct 25. doi: 10.1002/pros.24446.
    PubMed     Abstract available

  65. ODERDA M, Albisinni S, Benamran D, Calleris G, et al
    Accuracy of elastic fusion biopsy: Comparing prostate cancer detection between targeted and systematic biopsy.
    Prostate. 2022 Oct 19. doi: 10.1002/pros.24449.
    PubMed     Abstract available

  66. SATAPATHY S, Das CK, Aggarwal P, Sood A, et al
    Genomic characterization of metastatic castration-resistant prostate cancer patients undergoing PSMA radioligand therapy: A single-center experience.
    Prostate. 2022 Oct 19. doi: 10.1002/pros.24450.
    PubMed     Abstract available

  67. CHENG S, Yu X
    CTPC, a combined transcriptome data set of human prostate cancer cell lines.
    Prostate. 2022 Oct 7. doi: 10.1002/pros.24448.
    PubMed     Abstract available

  68. HARPER JB, Greenberg SE, Hunt TC, Cooney KA, et al
    Initial outcomes and insights from a novel high-risk prostate cancer screening clinic.
    Prostate. 2022 Oct 7. doi: 10.1002/pros.24447.
    PubMed     Abstract available

  69. OU W, Lei J, Li M, Zhang X, et al
    Ultrasound-based radiomics score for pre-biopsy prediction of prostate cancer to reduce unnecessary biopsies.
    Prostate. 2022 Oct 7. doi: 10.1002/pros.24442.
    PubMed     Abstract available

  70. HARTRAMPF PE, Weinzierl FX, Seitz AK, Kubler H, et al
    Any decline in prostate-specific antigen levels identifies survivors scheduled for prostate-specific membrane antigen-directed radioligand therapy.
    Prostate. 2022;82:1406-1412.
    PubMed     Abstract available

  71. VERMA S, Kushwaha PP, Shankar E, Ponsky LE, et al
    Increased cytokine gene expression and cognition risk associated with androgen deprivation therapy.
    Prostate. 2022;82:1389-1399.
    PubMed     Abstract available

  72. WONG WW, Hillman DW, Daniels TB, Vargas CE, et al
    A Phase II prospective study of hypofractionated proton therapy of prostate and pelvic lymph nodes: Acute effects on patient-reported quality of life.
    Prostate. 2022;82:1338-1345.
    PubMed     Abstract available

    September 2022
  73. LEE YHA, Hui JMH, Chan JSK, Liu K, et al
    Metformin use and mortality in Asian, diabetic patients with prostate cancer on androgen deprivation therapy: A population-based study.
    Prostate. 2022 Sep 30. doi: 10.1002/pros.24443.
    PubMed     Abstract available

  74. MUSTAFFA A, Emara S
    Safely omitting bone isotope scans in a cohort of grade group 2 prostate cancer.
    Prostate. 2022 Sep 29. doi: 10.1002/pros.24444.
    PubMed     Abstract available

  75. URABE F, Miki K, Kimura T, Sasaki H, et al
    Long-term outcomes of radical prostatectomy versus low-dose-rate brachytherapy in patients with intermediate-risk prostate cancer: Propensity score matched comparison.
    Prostate. 2022 Sep 29. doi: 10.1002/pros.24445.
    PubMed     Abstract available

  76. WANG S, Zhang C, Xu Z, Chen MH, et al
    Differential impact of PI3K/AKT/mTOR signaling on tumor initiation and progression in animal models of prostate cancer.
    Prostate. 2022 Sep 26. doi: 10.1002/pros.24441.
    PubMed     Abstract available

  77. ALAMIRI J, Britton CJ, Ahmed ME, Andrews JR, et al
    Radiographic paradoxical response in metastatic castrate-resistant prostate cancer (mCRPC) managed with new generation anti-androgens: a retrospective analysis.
    Prostate. 2022 Sep 11. doi: 10.1002/pros.24413.
    PubMed     Abstract available

  78. SCHMID FA, Lieger L, Saba K, Sigg S, et al
    Therapy decisions after diagnosis of prostate cancer in men with negative prostate MRI.
    Prostate. 2022 Sep 8. doi: 10.1002/pros.24435.
    PubMed     Abstract available

  79. LIN R, Yang Y, Wu E, Zhou M, et al
    SIRT2 promotes cell proliferation and migration through mediating ERK1/2 activation and lactosylceramide accumulation in prostate cancer.
    Prostate. 2022 Sep 8. doi: 10.1002/pros.24437.
    PubMed     Abstract available

  80. SCHOBER JP, Stensland KD, Moinzadeh A, Canes D, et al
    Holmium laser enucleation of the prostate in men on active surveillance for prostate cancer with refractory lower urinary tract symptoms secondary to enlarged prostates.
    Prostate. 2022 Sep 5. doi: 10.1002/pros.24433.
    PubMed     Abstract available

  81. KC M, Oral E, Rung AL, Trapido E, et al
    Prostate cancer aggressiveness and financial toxicity among prostate cancer patients.
    Prostate. 2022 Sep 5. doi: 10.1002/pros.24434.
    PubMed     Abstract available

    August 2022
  82. SEMIZ HS, Kucuk U, Kisa E, Keskinkilic M, et al
    CD47 (don't eat me signal) expression levels and its relationship with clinicopathologic features in early-stage prostate carcinoma.
    Prostate. 2022 Aug 28. doi: 10.1002/pros.24432.
    PubMed     Abstract available

  83. RUAN X, Huang D, Huang J, Xu D, et al
    Application of European-specific polygenic risk scores for predicting prostate cancer risk in different ancestry populations.
    Prostate. 2022 Aug 22. doi: 10.1002/pros.24431.
    PubMed     Abstract available

  84. KARELIA DN, Kim S, Plano D, Sharma AK, et al
    Seleno-aspirin compound AS-10 promotes histone acetylation ahead of suppressing androgen receptor transcription, G1 arrest, and apoptosis of prostate cancer cells.
    Prostate. 2022 Aug 22. doi: 10.1002/pros.24430.
    PubMed     Abstract available

  85. DYMANUS K, Howard LE, Oyekunle T, De Hoedt AM, et al
    Are higher pre-diagnosis follicle stimulating hormone levels associated with long-term prostate cancer risk?
    Prostate. 2022 Aug 18. doi: 10.1002/pros.24429.
    PubMed     Abstract available

  86. FILON MJ, Gillette AA, Yang B, Khemees TA, et al
    Prostate cancer cells demonstrate unique metabolism and substrate adaptability acutely after androgen deprivation therapy.
    Prostate. 2022 Aug 18. doi: 10.1002/pros.24428.
    PubMed     Abstract available

  87. MAYNARD JP, Godwin TN, Lu J, Vidal I, et al
    Localization of macrophage subtypes and neutrophils in the prostate tumor microenvironment and their association with prostate cancer racial disparities.
    Prostate. 2022 Aug 16. doi: 10.1002/pros.24424.
    PubMed     Abstract available

  88. TAKAMORI H, Urabe F, Matsuzaki J, Kimura S, et al
    Circulating microRNA profiling for prediction of oncological outcomes in prostate cancer patients following radical prostatectomy.
    Prostate. 2022 Aug 16. doi: 10.1002/pros.24427.
    PubMed     Abstract available

  89. TERRACCIANO D, La Civita E, Athanasiou A, Liotti A, et al
    New strategy for the identification of prostate cancer: The combination of Proclarix and the prostate health index.
    Prostate. 2022 Aug 16. doi: 10.1002/pros.24422.
    PubMed     Abstract available

  90. WANG S, Ryan Russell J, Drescher M, Park A, et al
    Prostate cancer grade downgrading at time of prostatectomy provides risk-stratification insight into future tumor behavior after prostatectomy.
    Prostate. 2022 Aug 3. doi: 10.1002/pros.24425.
    PubMed     Abstract available

  91. LOMBARDO R, Rovesti L, Cicione A, Gravina C, et al
    Serum levels of chromogranin are not predictive of poorly differentiated prostate cancer: Results from a multicenter radical prostatectomy cohort.
    Prostate. 2022 Aug 3. doi: 10.1002/pros.24412.
    PubMed     Abstract available

  92. KWAN EM, Wyatt AW
    Androgen receptor genomic alterations and treatment resistance in metastatic prostate cancer.
    Prostate. 2022;82 Suppl 1:S25-S36.
    PubMed     Abstract available

  93. SUTERA P, Deek MP, Van der Eecken K, Wyatt AW, et al
    Genomic biomarkers to guide precision radiotherapy in prostate cancer.
    Prostate. 2022;82 Suppl 1:S73-S85.
    PubMed     Abstract available

  94. KHAN HM, Cheng HH
    Germline genetics of prostate cancer.
    Prostate. 2022;82 Suppl 1:S3-S12.
    PubMed     Abstract available

    Clinical implications of homologous recombination repair mutations in prostate cancer.
    Prostate. 2022;82 Suppl 1:S45-S59.
    PubMed     Abstract available

  96. COTTER K, Rubin MA
    The evolving landscape of prostate cancer somatic mutations.
    Prostate. 2022;82 Suppl 1:S13-S24.
    PubMed     Abstract available

    Genetics and genomics of prostate cancer and therapeutic implications.
    Prostate. 2022;82 Suppl 1:S1-S2.

  98. MIZUNO K, Beltran H
    Future directions for precision oncology in prostate cancer.
    Prostate. 2022;82 Suppl 1:S86-S96.
    PubMed     Abstract available

    PTEN-PI3K pathway alterations in advanced prostate cancer and clinical implications.
    Prostate. 2022;82 Suppl 1:S60-S72.
    PubMed     Abstract available

  100. LI G, Xia YF, Huang YX, Okat D, et al
    Better preservation of erectile function in localized prostate cancer patients with modern proton therapy: Is it cost-effective?
    Prostate. 2022 Aug 1. doi: 10.1002/pros.24417.
    PubMed     Abstract available

  101. UCAR T, Gunduz N, Demirci E, Culpan M, et al
    Comparison of 68Ga-PSMA PET/CT and mp-MRI in regard to local staging for prostate cancer with histopathological results: A retrospective study.
    Prostate. 2022 Aug 1. doi: 10.1002/pros.24420.
    PubMed     Abstract available

    July 2022
  102. YAZGAN SC, Yekeduz E, Utkan G, Urun Y, et al
    Prognostic role of pan-immune-inflammation value in patients with metastatic castration-resistant prostate cancer treated with androgen receptor-signaling inhibitors.
    Prostate. 2022 Jul 28. doi: 10.1002/pros.24419.
    PubMed     Abstract available

  103. KHAN S, Vohra S, Farnan L, Elmore SNC, et al
    Using health insurance claims data to assess long-term disease progression in a prostate cancer cohort.
    Prostate. 2022 Jul 26. doi: 10.1002/pros.24418.
    PubMed     Abstract available

  104. WANG Y, Tang Y, Gao X, Gan Y, et al
    Optimization of prostate cancer patient lymph node staging via the integration of neutrophil-lymphocyte ratios, platelet-lymphocyte ratios, and (68) Ga-PSMA-PET-derived SUVmax values.
    Prostate. 2022 Jul 21. doi: 10.1002/pros.24415.
    PubMed     Abstract available

  105. MIYAHIRA AK, Soule HR
    The 28th Annual Prostate Cancer Foundation Scientific Retreat report.
    Prostate. 2022 Jul 18. doi: 10.1002/pros.24409.
    PubMed     Abstract available

  106. MODONUTTI D, Majdalany SE, Corsi N, Li P, et al
    A novel prognostic model predicting overall survival in patients with metastatic castration-resistant prostate cancer receiving standard chemotherapy: A multi-trial cohort analysis.
    Prostate. 2022 Jul 5. doi: 10.1002/pros.24403.
    PubMed     Abstract available

  107. RAMIREZ-TORRES A, Reagan AL, Howard LE, Wiggins E, et al
    Racial differences in circulating mitochondria-derived peptides may contribute to prostate cancer health disparities.
    Prostate. 2022 Jul 5. doi: 10.1002/pros.24398.
    PubMed     Abstract available

    June 2022
  108. YANAGISAWA T, Kimura T, Hata K, Narita S, et al
    Does castration status affect docetaxel-related adverse events? :Identification of risk factors for docetaxel-related adverse events in metastatic prostate cancer.
    Prostate. 2022 Jun 29. doi: 10.1002/pros.24406.
    PubMed     Abstract available

  109. CASADO-LLOMBART S, Ajami T, Consuegra-Fernandez M, Carreras E, et al
    Gene variation impact on prostate cancer progression: Lymphocyte modulator, activation, and cell adhesion gene variant contribution.
    Prostate. 2022 Jun 29. doi: 10.1002/pros.24407.
    PubMed     Abstract available

  110. BRAY AW, Duan R, Malalur P, Drusbosky LM, et al
    Elevated serum CEA is associated with liver metastasis and distinctive circulating tumor DNA alterations in patients with castration-resistant prostate cancer.
    Prostate. 2022 Jun 29. doi: 10.1002/pros.24400.
    PubMed     Abstract available

  111. MIURA Y, Hatakeyama S, Narita S, Kimura T, et al
    Effect of upfront intensive therapy on oncological outcomes in older patients with high tumor burden metastatic castration-sensitive prostate cancer: A multicenter retrospective study.
    Prostate. 2022 Jun 23. doi: 10.1002/pros.24404.
    PubMed     Abstract available

  112. YANG T, Liu Y, Chen S, Tian J, et al
    Serum prolactin level as a predictive factor for abiraterone response in patients with metastatic castration-resistant prostate cancer.
    Prostate. 2022 Jun 23. doi: 10.1002/pros.24402.
    PubMed     Abstract available

  113. HEARD JR, Huang AJ, Werle L, Adler K, et al
    Definitive treatment choice among Black immigrants with prostate cancer: Analysis of patient surveys distributed at a single safety-net institution.
    Prostate. 2022 Jun 23. doi: 10.1002/pros.24399.
    PubMed     Abstract available

  114. STENZL A, Szmulewitz RZ, Petrylak D, Holzbeierlein J, et al
    The impact of enzalutamide on quality of life in men with metastatic hormone-sensitive prostate cancer based on prior therapy, risk, and symptom subgroups.
    Prostate. 2022 Jun 8. doi: 10.1002/pros.24396.
    PubMed     Abstract available

  115. LIU AJ, Kosiorek HE, Ueberroth BE, Jaeger E, et al
    The impact of genetic aberrations on response to radium-223 treatment for castration-resistant prostate cancer with bone metastases.
    Prostate. 2022 Jun 2. doi: 10.1002/pros.24375.
    PubMed     Abstract available

  116. SORCE G, Hoeh B, Flammia RS, Chierigo F, et al
    Rates of metastatic prostate cancer in newly diagnosed patients: Numbers needed to image according to risk level.
    Prostate. 2022 Jun 2. doi: 10.1002/pros.24376.
    PubMed     Abstract available

  117. CHO HL, Murthy V, Mouw KW, D'Amico AV, et al
    Second malignancy probabilities in patients with prostate cancer treated with whole pelvis radiation therapy versus prostate only radiation therapy.
    Prostate. 2022 Jun 2. doi: 10.1002/pros.24362.
    PubMed     Abstract available

  118. ABDI B, Basset N, Perrot E, Benderra MA, et al
    DNA damage repair gene germline profiling for metastatic prostate cancer patients of different ancestries.
    Prostate. 2022 Jun 2. doi: 10.1002/pros.24374.
    PubMed     Abstract available

  119. MUNOZ-MORENO L, Carmena MJ, Prieto JC, Schally AV, et al
    Tumorigenic transformation of human prostatic epithelial cell line RWPE-1 by growth hormone-releasing hormone (GHRH).
    Prostate. 2022;82:933-941.
    PubMed     Abstract available

  120. FUJIWARA M, Numao N, Yamamoto S, Ishikawa Y, et al
    Predictive ability of prebiopsy magnetic resonance imaging and biopsy for side-specific negative lymph node metastasis at radical prostatectomy.
    Prostate. 2022;82:904-910.
    PubMed     Abstract available

  121. HOLZE S, Lemaire E, Mende M, Neuhaus P, et al
    Quality of life after robotic-assisted and laparoscopic radical prostatectomy: Results of a multicenter randomized controlled trial (LAP-01).
    Prostate. 2022;82:894-903.
    PubMed     Abstract available

  122. RATNANI P, Dovey Z, Parekh S, Sobotka S, et al
    Prostate MRI percentage tumor involvement or "PI-RADS percent" as a predictor of adverse surgical pathology.
    Prostate. 2022;82:970-983.
    PubMed     Abstract available

    May 2022
  123. ASKER H, Yilmaz-Oral D, Oztekin CV, Gur S, et al
    An update on the current status and future prospects of erectile dysfunction following radical prostatectomy.
    Prostate. 2022 May 17. doi: 10.1002/pros.24366.
    PubMed     Abstract available

  124. PELLEGRINO F, Stabile A, Mazzone E, Sorce G, et al
    Does previous prostate surgery affect multiparametric magnetic resonance imaging accuracy in detecting clinically significant prostate cancer? Results from a single institution series.
    Prostate. 2022 May 10. doi: 10.1002/pros.24368.
    PubMed     Abstract available

  125. HE Y, Shen Q, Fu W, Wang H, et al
    Optimized grade group for reporting prostate cancer grade in systematic and MRI-targeted biopsies.
    Prostate. 2022 May 10. doi: 10.1002/pros.24365.
    PubMed     Abstract available

  126. MORGANS AK, Chen YH, Jarrard DF, Carducci M, et al
    Association between baseline body mass index and survival in men with metastatic hormone-sensitive prostate cancer: ECOG-ACRIN CHAARTED E3805.
    Prostate. 2022 May 10. doi: 10.1002/pros.24369.
    PubMed     Abstract available

    Orphan receptors in prostate cancer.
    Prostate. 2022 May 10. doi: 10.1002/pros.24370.
    PubMed     Abstract available

  128. KEEGAN NM, Vasselman SE, Barnett ES, Nweji B, et al
    Clinical annotations for prostate cancer research: Defining data elements, creating a reproducible analytical pipeline, and assessing data quality.
    Prostate. 2022 May 10. doi: 10.1002/pros.24363.
    PubMed     Abstract available

  129. DENMEADE S, Antonarakis ES, Markowski MC
    Bipolar androgen therapy (BAT): A patient's guide.
    Prostate. 2022;82:753-762.
    PubMed     Abstract available

  130. VITEK RA, Huang W, Geiger PG, Heninger E, et al
    Fresh tissue procurement and preparation for multicompartment and multimodal analysis of the prostate tumor microenvironment.
    Prostate. 2022;82:836-849.
    PubMed     Abstract available

  131. LUNACEK A, Tischler M, Mrstik C, Hebenstreit D, et al
    Effects of cycling and rowing on serum concentrations of prostate-specific antigen: A randomized study of 101 male subjects.
    Prostate. 2022;82:804-808.
    PubMed     Abstract available

    April 2022
  132. BOSLAND MC, Horton L, Condon MS
    Effects of green tea on prostate carcinogenesis in rat models and a human prostate cancer xenograft model.
    Prostate. 2022 Apr 29. doi: 10.1002/pros.24364.
    PubMed     Abstract available

  133. WITHROW D, Pilleron S, Nikita N, Ferlay J, et al
    Current and projected number of years of life lost due to prostate cancer: A global study.
    Prostate. 2022 Apr 25. doi: 10.1002/pros.24360.
    PubMed     Abstract available

  134. WANG M, Qi J, George AK, Semerjian A, et al
    The added influence of genomics and post-MRI confirmatory biopsy results to MRI results alone on medical decision making for men with favorable risk prostate cancer being considered for active surveillance.
    Prostate. 2022 Apr 25. doi: 10.1002/pros.24357.
    PubMed     Abstract available

  135. HU Q, Hong X, Xu L, Jia R, et al
    A nomogram for accurately predicting the pathological upgrading of prostate cancer, based on (68) Ga-PSMA PET/CT.
    Prostate. 2022 Apr 25. doi: 10.1002/pros.24358.
    PubMed     Abstract available

  136. YUEN KC, Tran B, Anton A, Hamidi H, et al
    Molecular classification of hormone-sensitive and castration-resistant prostate cancer, using nonnegative matrix factorization molecular subtyping of primary and metastatic specimens.
    Prostate. 2022 Apr 18. doi: 10.1002/pros.24346.
    PubMed     Abstract available

  137. PITAK-ARNNOP P, Messer-Peti R, Tangmanee C, Neff A, et al
    Prostate cancer awareness among transgender women after gender-affirming surgery.
    Prostate. 2022 Apr 13. doi: 10.1002/pros.24355.
    PubMed     Abstract available

  138. MORI JO, Shafran JS, Stojanova M, Katz MH, et al
    Novel forms of prostate cancer chemoresistance to successful androgen deprivation therapy demand new approaches: Rationale for targeting BET proteins.
    Prostate. 2022 Apr 11. doi: 10.1002/pros.24351.
    PubMed     Abstract available

  139. FLAMMIA RS, Hoeh B, Sorce G, Chierigo F, et al
    Contemporary seminal vesicle invasion rates in NCCN high-risk prostate cancer patients.
    Prostate. 2022 Apr 11. doi: 10.1002/pros.24350.
    PubMed     Abstract available

  140. LV X, Li Y, Li R, Guan X, et al
    Relationships of sleep traits with prostate cancer risk: A prospective study of 213,999 UK Biobank participants.
    Prostate. 2022 Apr 11. doi: 10.1002/pros.24345.
    PubMed     Abstract available

  141. SORCE G, Flammia RS, Hoeh B, Chierigo F, et al
    Grade and stage misclassification in intermediate unfavorable-risk prostate cancer radiotherapy candidates.
    Prostate. 2022 Apr 1. doi: 10.1002/pros.24349.
    PubMed     Abstract available

  142. YAMAGUCHI M, Murata T, Ramos JW
    Overexpression of regucalcin blocks the migration, invasion, and bone metastatic activity of human prostate cancer cells: Crosstalk between cancer cells and bone cells.
    Prostate. 2022 Apr 1. doi: 10.1002/pros.24348.
    PubMed     Abstract available

  143. ZHOU Z, Liang Z, Zuo Y, Zhou Y, et al
    Development of a nomogram combining multiparametric magnetic resonance imaging and PSA-related parameters to enhance the detection of clinically significant cancer across different region.
    Prostate. 2022;82:556-565.
    PubMed     Abstract available

  144. CHEN Z, Wu J, Sun K, He Y, et al
    Risk model based on MRI fusion biopsy characteristics predicts biochemical recurrence after radical prostatectomy.
    Prostate. 2022;82:566-575.
    PubMed     Abstract available

  145. LINDH C, Samaratunga H, Delahunt B, Bergstrom R, et al
    Ductal and acinar components of mixed prostatic adenocarcinoma frequently have a common clonal origin.
    Prostate. 2022;82:576-583.
    PubMed     Abstract available

  146. WEI X, Roudier MP, Kwon OJ, Lee JD, et al
    Paracrine Wnt signaling is necessary for prostate epithelial proliferation.
    Prostate. 2022;82:517-530.
    PubMed     Abstract available

    March 2022
  147. GRAHAM LS, Schweizer MT
    Mismatch repair deficiency and clinical implications in prostate cancer.
    Prostate. 2022 Mar 31. doi: 10.1002/pros.24343.
    PubMed     Abstract available

  148. PREISSER F, Heinze A, S Abrams-Pompe R, Budaus L, et al
    Impact of positive surgical margin length and Gleason grade at the margin on oncologic outcomes in patients with nonorgan-confined prostate cancer.
    Prostate. 2022 Mar 28. doi: 10.1002/pros.24341.
    PubMed     Abstract available

  149. SINGH CK, Denu RA, Nihal M, Shabbir M, et al
    PLK4 is upregulated in prostate cancer and its inhibition reduces centrosome amplification and causes senescence.
    Prostate. 2022 Mar 25. doi: 10.1002/pros.24342.
    PubMed     Abstract available

  150. MAO F, Kong Y, Liu J, Rao X, et al
    Diptoindonesin G antagonizes AR signaling and enhances the efficacy of antiandrogen therapy in prostate cancer.
    Prostate. 2022 Mar 24. doi: 10.1002/pros.24336.
    PubMed     Abstract available

  151. LUNDGREN PO, Tribukait B, Kjellman A, Norming U, et al
    Serum thymidine kinase 1 concentration as a predictive biomarker in prostate cancer.
    Prostate. 2022 Mar 16. doi: 10.1002/pros.24335.
    PubMed     Abstract available

  152. SADAGHIANI MS, Sheikhbahaei S, Werner RA, Pienta KJ, et al
    (177) Lu-PSMA radioligand therapy effectiveness in metastatic castration-resistant prostate cancer: An updated systematic review and meta-analysis.
    Prostate. 2022 Mar 14. doi: 10.1002/pros.24325.
    PubMed     Abstract available

  153. ZHANG T, Kephart J, Bronson E, Anand M, et al
    Prospective clinical trial of disulfiram plus copper in men with metastatic castration-resistant prostate cancer.
    Prostate. 2022 Mar 14. doi: 10.1002/pros.24329.
    PubMed     Abstract available

  154. ANTONARAKIS ES, Tierno M, Fisher V, Tukachinsky H, et al
    Clinical and pathological features associated with circulating tumor DNA content in real-world patients with metastatic prostate cancer.
    Prostate. 2022 Mar 14. doi: 10.1002/pros.24331.
    PubMed     Abstract available

  155. SENTANA-LLEDO D, Sartor O, Balk SP, Einstein DJ, et al
    Immune mechanisms behind prostate cancer in men of African ancestry: A review.
    Prostate. 2022 Mar 7. doi: 10.1002/pros.24333.
    PubMed     Abstract available

  156. BECKMANN KR, Bangma CH, Helleman J, Bjartell A, et al
    Comparison of outcomes of different biopsy schedules among men on active surveillance for prostate cancer: An analysis of the G.A.P.3 global consortium database.
    Prostate. 2022 Mar 7. doi: 10.1002/pros.24330.
    PubMed     Abstract available

  157. HINOJOSA-GONZALEZ DE, Roblesgil-Medrano A, Torres-Martinez M, Alanis-Garza C, et al
    Single-port versus multiport robotic-assisted radical prostatectomy: A systematic review and meta-analysis on the da Vinci SP platform.
    Prostate. 2022;82:405-414.
    PubMed     Abstract available

  158. LEITSMANN C, Uhlig A, Bremmer F, Mut TT, et al
    Impact of mpMRI targeted biopsy on intraoperative nerve-sparing (NeuroSAFE) during robot-assisted laparoscopic radical prostatectomy.
    Prostate. 2022;82:493-501.
    PubMed     Abstract available

  159. KOPARAL MY, Sozen TS, Karsiyakali N, Aslan G, et al
    Comparison of transperineal and transrectal targeted prostate biopsy using Mahalanobis distance matching within propensity score caliper method: A multicenter study of Turkish Urooncology Association.
    Prostate. 2022;82:425-432.
    PubMed     Abstract available

    February 2022
  160. CHIERIGO F, Borghesi M, Wurnschimmel C, Flammia RS, et al
    Survival after radical prostatectomy versus radiation therapy in clinical node-positive prostate cancer.
    Prostate. 2022 Feb 28. doi: 10.1002/pros.24317.
    PubMed     Abstract available

  161. PURAYIL HT, Daaka Y
    betaArrestin1 regulates glucocorticoid receptor mitogenic signaling in castration-resistant prostate cancer.
    Prostate. 2022 Feb 28. doi: 10.1002/pros.24324.
    PubMed     Abstract available

  162. LIU JM, Chen YT, Wu CT, Hsu WL, et al
    Androgen deprivation therapy for prostate cancer and the risk of thyroid diseases.
    Prostate. 2022 Feb 28. doi: 10.1002/pros.24323.
    PubMed     Abstract available

  163. K C M, Oral E, Rung AL, Trapido EJ, et al
    Neighborhood deprivation and risk of mortality among men with prostate cancer: Findings from a long-term follow-up study.
    Prostate. 2022 Feb 24. doi: 10.1002/pros.24320.
    PubMed     Abstract available

  164. KANEKO M, Fukuda N, Nagano H, Yamada K, et al
    Artificial intelligence trained with integration of multiparametric MR-US imaging data and fusion biopsy trajectory-proven pathology data for 3D prediction of prostate cancer: A proof-of-concept study.
    Prostate. 2022 Feb 22. doi: 10.1002/pros.24321.
    PubMed     Abstract available

  165. IZOL V, Ok F, Aslan G, Akdogan B, et al
    Effect of pelvic lymph node dissection and its extent on oncological outcomes in intermediate-risk prostate cancer patients: A multicenter study of the Turkish Uro-oncology Association.
    Prostate. 2022 Feb 21. doi: 10.1002/pros.24318.
    PubMed     Abstract available

  166. OZBEK B, Ertunc O, Erickson A, Vidal ID, et al
    Multiplex immunohistochemical phenotyping of T cells in primary prostate cancer.
    Prostate. 2022 Feb 21. doi: 10.1002/pros.24315.
    PubMed     Abstract available

  167. HOEH B, Flammia RS, Hohenhorst L, Sorce G, et al
    Non-organ confined stage and upgrading rates in exclusive PSA high-risk prostate cancer patients.
    Prostate. 2022 Feb 21. doi: 10.1002/pros.24313.
    PubMed     Abstract available

  168. HOEH B, Wurnschimmel C, Flammia RS, Horlemann B, et al
    Effect of chemotherapy in metastatic prostate cancer according to race/ethnicity groups.
    Prostate. 2022 Feb 21. doi: 10.1002/pros.24312.
    PubMed     Abstract available

  169. PAGEL CN, Kularathna PK, Sanaei R, Young ND, et al
    Protease-activated receptor-2 dependent and independent responses of bone cells to prostate cancer cell secretory products.
    Prostate. 2022 Feb 15. doi: 10.1002/pros.24316.
    PubMed     Abstract available

  170. WANG Y, Abenojar EC, Wang J, de Leon AC, et al
    Development of a novel castration-resistant orthotopic prostate cancer model in New Zealand White rabbit.
    Prostate. 2022 Feb 15. doi: 10.1002/pros.24314.
    PubMed     Abstract available

  171. STAMIS SA, Heath EI, Lucas S, Boerner J, et al
    Alcohol dehydrogenase expression patterns in normal prostate, benign prostatic hyperplasia, and prostatic adenocarcinoma in African American and Caucasian men.
    Prostate. 2022 Feb 8. doi: 10.1002/pros.24310.
    PubMed     Abstract available

  172. SUN Y, Ai JZ, Jin X, Liu LR, et al
    IL-8 protects prostate cancer cells from GSK-3beta-induced oxidative stress by activating the mTOR signaling pathway.
    Prostate. 2022;82:401-402.

  173. URAKAMI A, Arimura H, Takayama Y, Kinoshita F, et al
    Stratification of prostate cancer patients into low- and high-grade groups using multiparametric magnetic resonance radiomics with dynamic contrast-enhanced image joint histograms.
    Prostate. 2022;82:330-344.
    PubMed     Abstract available

  174. WENZEL M, Colla Ruvolo C, Wurnschimmel C, Nocera L, et al
    Response to the letter to the editor: "Don't throw the baby out with the bath water" by Horsley et al.
    Prostate. 2022;82:399-400.

  175. HORSLEY PJ, Kneebone A, Eade TN, Hruby G, et al
    Don't throw the baby out with the bath water.
    Prostate. 2022;82:397-398.

  176. MA C, Downes M, Jain R, Ientilucci M, et al
    Prevalence of adverse pathology features in grade group 2 prostatectomy specimens with syn- or metachronous metastatic disease.
    Prostate. 2022;82:345-351.
    PubMed     Abstract available

  177. ZENNER ML, Helou YB, Deaton RJ, Sverdlov M, et al
    Advanced glycation end-products (AGEs) are lower in prostate tumor tissue and inversely related to proportion of West African ancestry.
    Prostate. 2022;82:306-313.
    PubMed     Abstract available

  178. ARCOT R, Cher ML, Qi J, Linsell SM, et al
    Delayed radical prostatectomy after a period of active surveillance is not associated with the use of secondary treatments compared with immediate prostatectomy.
    Prostate. 2022;82:323-329.
    PubMed     Abstract available

  179. TAN YG, Fang AHS, Lim JKS, Khalid F, et al
    Incorporating artificial intelligence in urology: Supervised machine learning algorithms demonstrate comparative advantage over nomograms in predicting biochemical recurrence after prostatectomy.
    Prostate. 2022;82:298-305.
    PubMed     Abstract available

  180. MA H, Xu W, Ni J, Zhao N, et al
    Phase I clinical trial of HC-1119 soft capsule in Chinese healthy adult male subjects: Pharmacokinetics and safety of single-dose proportionality and effects of food.
    Prostate. 2022;82:276-285.
    PubMed     Abstract available

  181. LI N, Song WJ, Gao J, Xu ZP, et al
    The prognostic nutritional index predicts the biochemical recurrence of patients treated with robot-assisted laparoscopic radical prostatectomy.
    Prostate. 2022;82:221-226.
    PubMed     Abstract available

  182. AUSSAVAVIROJEKUL P, Hoonlor A, Srinualnad S
    Optimization of clinical risk-factor interpretation and radiological findings with machine learning for PIRADS category 3 patients.
    Prostate. 2022;82:235-244.
    PubMed     Abstract available

  183. SIEDOW M, Eisner M, Yaney A, Washington I, et al
    Impact of prostate biopsy secondary pathology review on radiotherapy management.
    Prostate. 2022;82:210-215.
    PubMed     Abstract available

    January 2022
  184. LUNA VELEZ MV, Paulino da Silva Filho O, Verhaegh GW, van Hooij O, et al
    Delivery of antisense oligonucleotides for splice-correction of androgen receptor pre-mRNA in castration-resistant prostate cancer models using cell-penetrating peptides.
    Prostate. 2022 Jan 31. doi: 10.1002/pros.24309.
    PubMed     Abstract available

  185. GARCIA-MARQUES F, Liu S, Totten SM, Bermudez A, et al
    Protein signatures to distinguish aggressive from indolent prostate cancer.
    Prostate. 2022 Jan 31. doi: 10.1002/pros.24307.
    PubMed     Abstract available

  186. ZHAO R, Lv Y, Feng T, Zhang R, et al
    ATF6alpha promotes prostate cancer progression by enhancing PLA2G4A-mediated arachidonic acid metabolism and protecting tumor cells against ferroptosis.
    Prostate. 2022 Jan 28. doi: 10.1002/pros.24308.
    PubMed     Abstract available

  187. STOVER EH, Oh C, Keskula P, Choudhury AD, et al
    Implementation of a prostate cancer-specific targeted sequencing panel for credentialing of patient-derived cell lines and genomic characterization of patient samples.
    Prostate. 2022 Jan 27. doi: 10.1002/pros.24305.
    PubMed     Abstract available

  188. MOLL JM, Hofland J, Teubel WJ, de Ridder CMA, et al
    Abiraterone switches castration-resistant prostate cancer dependency from adrenal androgens towards androgen receptor variants and glucocorticoid receptor signalling.
    Prostate. 2022 Jan 17. doi: 10.1002/pros.24297.
    PubMed     Abstract available

  189. ZHU S, Zhang Z, Zhang H, Liu Z, et al
    DNA-repair status should be assessed in treatment-emergent neuroendocrine prostate cancer before platinum-based therapy.
    Prostate. 2022 Jan 17. doi: 10.1002/pros.24292.
    PubMed     Abstract available

  190. ZHOU J, Chen H, Wu Y, Shi B, et al
    Plasma IL-6 and TNF-alpha levels correlate significantly with grading changes in localized prostate cancer.
    Prostate. 2022 Jan 17. doi: 10.1002/pros.24299.
    PubMed     Abstract available

  191. CAO Y, Song DY, Deville C, DeWeese TL, et al
    Radiating the prostate bed in relapsed oligometastatic prostate cancer: How comprehensive should we be?
    Prostate. 2022 Jan 11. doi: 10.1002/pros.24301.
    PubMed     Abstract available

  192. RASPIN K, O'Malley DE, Marthick JR, Donovan S, et al
    Analysis of a large prostate cancer family identifies novel and recurrent gene fusion events providing evidence for inherited predisposition.
    Prostate. 2022 Jan 7. doi: 10.1002/pros.24300.
    PubMed     Abstract available

  193. VLACHOSTERGIOS PJ, Niaz MJ, Thomas C, Christos PJ, et al
    Pilot study of the diagnostic utility of (89) Zr-df-IAB2M and (68) Ga-PSMA-11 PET imaging and multiparametric MRI in localized prostate cancer.
    Prostate. 2022 Jan 5. doi: 10.1002/pros.24294.
    PubMed     Abstract available

  194. SEREF C, Acar O, Kilic M, Vural M, et al
    Histologically benign PI-RADS 4 and 5 lesions contain cancer-associated epigenetic alterations.
    Prostate. 2022;82:145-153.
    PubMed     Abstract available

  195. YUAN W, Liu B, Sanda M, Wei R, et al
    Glycoforms of human prostate-specific membrane antigen (PSMA) in human cells and prostate tissue.
    Prostate. 2022;82:132-144.
    PubMed     Abstract available

  196. WIDJAJA L, Derlin T, Ross TL, Bengel FM, et al
    Pretherapeutic estimated glomerular filtration rate predicts development of chronic kidney disease in patients receiving PSMA-targeted radioligand therapy.
    Prostate. 2022;82:86-96.
    PubMed     Abstract available

    December 2021
  197. SNIPAITIENE K, Bakavicius A, Lazutka JR, Ulys A, et al
    Urinary microRNAs can predict response to abiraterone acetate in castration resistant prostate cancer: A pilot study.
    Prostate. 2021 Dec 30. doi: 10.1002/pros.24293.
    PubMed     Abstract available

  198. MIKOSHI A, Miyai K, Hamabe F, Edo H, et al
    MRI-detectability and histological factors of prostate cancer including intraductal carcinoma and cribriform pattern.
    Prostate. 2021 Dec 28. doi: 10.1002/pros.24291.
    PubMed     Abstract available

  199. SIENKIEWICZ K, Yang C, Paschal BM, Ratan A, et al
    Genomic analyses of the metastasis-derived prostate cancer cell lines LNCaP, VCaP, and PC3-AR.
    Prostate. 2021 Dec 24:e24290. doi: 10.1002/pros.24290.
    PubMed     Abstract available

  200. HE H, Han D, Xu F, Lyu J, et al
    How socioeconomic and clinical factors impact prostate-cancer-specific and other-cause mortality in prostate cancer stratified by clinical stage: Competing-risk analysis.
    Prostate. 2021 Dec 20. doi: 10.1002/pros.24287.
    PubMed     Abstract available

  201. URABE F, Miki K, Kimura T, Sasaki H, et al
    Clinical significance of unfavorable findings in intermediate-risk prostate cancer patients for predicting treatment outcomes after contemporary, dose-escalated multimodal radiotherapy.
    Prostate. 2021 Dec 16. doi: 10.1002/pros.24289.
    PubMed     Abstract available

  202. KAUFMANN B, Saba K, Schmidli TS, Stutz S, et al
    Prostate cancer detection rate in men undergoing transperineal template-guided saturation and targeted prostate biopsy.
    Prostate. 2021 Dec 16. doi: 10.1002/pros.24286.
    PubMed     Abstract available

  203. BARLOW SK, Oyekunle T, Janes JL, De Hoedt AM, et al
    Prostate weight and prostate cancer outcomes after radical prostatectomy: Results from the SEARCH cohort study.
    Prostate. 2021 Dec 14. doi: 10.1002/pros.24283.
    PubMed     Abstract available

  204. LEFEBVRE F, Blanchet-Deverly A, Michineau L, Blanchet P, et al
    Metabolic syndrome and prostate cancer in Afro-Caribbean men.
    Prostate. 2021 Dec 14:e24281. doi: 10.1002/pros.24281.
    PubMed     Abstract available

  205. POCKROS B, Stensland KD, Parries M, Frankenberger E, et al
    Preoperative MRI PI-RADS scores are associated with prostate cancer upstaging on surgical pathology.
    Prostate. 2021 Dec 8. doi: 10.1002/pros.24280.
    PubMed     Abstract available

  206. ZAREI A, Javid H, Sanjarian S, Senemar S, et al
    Metagenomics studies for the diagnosis and treatment of prostate cancer.
    Prostate. 2021 Dec 2. doi: 10.1002/pros.24276.
    PubMed     Abstract available

  207. MATTI B, Reeves F, Prouse M, Zargar-Shoshtari K, et al
    The impact of the extent and location of positive surgical margins on the risk of biochemical recurrence following radical prostatectomy in men with Gleason 7 prostate cancers.
    Prostate. 2021;81:1428-1434.
    PubMed     Abstract available

  208. NAYAN M, Salari K, Bozzo A, Ganglberger W, et al
    Predicting survival after radical prostatectomy: Variation of machine learning performance by race.
    Prostate. 2021;81:1355-1364.
    PubMed     Abstract available

  209. YAMOAH K, Asamoah FA, Abrahams AOD, Awasthi S, et al
    Prostate tumors of native men from West Africa show biologically distinct pathways-A comparative genomic study.
    Prostate. 2021;81:1402-1410.
    PubMed     Abstract available

  210. TAKEZAWA K, Fujita K, Matsushita M, Motooka D, et al
    The Firmicutes/Bacteroidetes ratio of the human gut microbiota is associated with prostate enlargement.
    Prostate. 2021;81:1287-1293.
    PubMed     Abstract available

  211. WENZEL M, Wurnschimmel C, Chierigo F, Tian Z, et al
    Increased risk of postoperative in-hospital complications after radical prostatectomy in patients with prior organ transplant.
    Prostate. 2021;81:1294-1302.
    PubMed     Abstract available

    November 2021
  212. NAKAYAMA H, Sekine Y, Oka D, Miyazawa Y, et al
    Combination therapy with novel androgen receptor antagonists and statin for castration-resistant prostate cancer.
    Prostate. 2021 Nov 29. doi: 10.1002/pros.24274.
    PubMed     Abstract available

  213. VESTRIS PG, Gourtaud G, Senechal C, Sadreux Y, et al
    Overall and progression-free survival of Afro-Caribbean men with metastatic castration-resistant prostate cancer (mCRPC).
    Prostate. 2021 Nov 25. doi: 10.1002/pros.24270.
    PubMed     Abstract available

  214. PLAMBECK BD, Wang LL, Mcgirr S, Jiang J, et al
    Effects of the 2012 and 2018 US preventive services task force prostate cancer screening guidelines on pathologic outcomes after prostatectomy.
    Prostate. 2021 Nov 22. doi: 10.1002/pros.24261.
    PubMed     Abstract available

  215. PREISSER F, Wurnschimmel C, Pose RM, Heinze A, et al
    Concordance of biopsy and pathologic ISUP grading in salvage radical prostatectomy patients for recurrent prostate cancer.
    Prostate. 2021 Nov 22. doi: 10.1002/pros.24268.
    PubMed     Abstract available

  216. NAKAZAWA M, Fang M, H Marshall C, Lotan TL, et al
    Clinical and genomic features of SPOP-mutant prostate cancer.
    Prostate. 2021 Nov 15. doi: 10.1002/pros.24269.
    PubMed     Abstract available

  217. TRYGGESTAD AMA, Axcrona K, Axcrona U, Bigalke I, et al
    Long-term first-in-man Phase I/II study of an adjuvant dendritic cell vaccine in patients with high-risk prostate cancer after radical prostatectomy.
    Prostate. 2021 Nov 11. doi: 10.1002/pros.24267.
    PubMed     Abstract available

  218. HANSKE J, Risse Y, Roghmann F, Pucheril D, et al
    Comparison of prostate cancer detection rates in patients undergoing MRI/TRUS fusion prostate biopsy with two different software-based systems.
    Prostate. 2021 Nov 3. doi: 10.1002/pros.24264.
    PubMed     Abstract available

  219. MIYAHIRA AK, Zarif JC, Coombs CC, Flavell RR, et al
    Prostate cancer research in the 21st century; report from the 2021 Coffey-Holden prostate cancer academy meeting.
    Prostate. 2021 Nov 3. doi: 10.1002/pros.24262.
    PubMed     Abstract available

    October 2021
  220. SHI Z, Lu L, Resurreccion WK, Yang W, et al
    Association of germline rare pathogenic mutations in guideline-recommended genes with prostate cancer progression: A meta-analysis.
    Prostate. 2021 Oct 21. doi: 10.1002/pros.24252.
    PubMed     Abstract available

  221. PILLING A, Kim SH, Hwang C
    Androgen receptor negatively regulates mitotic checkpoint signaling to induce docetaxel resistance in castration-resistant prostate cancer.
    Prostate. 2021 Oct 21. doi: 10.1002/pros.24257.
    PubMed     Abstract available

  222. LUO LS, Jiang JF, Luan HH, Zi H, et al
    Spatial and temporal patterns of prostate cancer burden and their association with Socio-Demographic Index in Asia, 1990-2019.
    Prostate. 2021 Oct 18. doi: 10.1002/pros.24258.
    PubMed     Abstract available

  223. KIM S, Li L, Zhang J, Jiang C, et al
    Aqueous metabolome of tissue-specific conditional Pten-knockout mouse prostate cancer and TRAMP neuroendocrine carcinoma.
    Prostate. 2021 Oct 18. doi: 10.1002/pros.24256.
    PubMed     Abstract available

  224. HOEH B, Wurnschimmel C, Flammia RS, Horlemann B, et al
    Cancer-specific survival after radical prostatectomy versus external beam radiotherapy in high-risk and very high-risk African American prostate cancer patients.
    Prostate. 2021 Oct 18. doi: 10.1002/pros.24253.
    PubMed     Abstract available

  225. WENZEL M, Colla Ruvolo C, Wurnschimmel C, Nocera L, et al
    Survival rates with external beam radiation therapy in newly diagnosed elderly metastatic prostate cancer patients.
    Prostate. 2021 Oct 11. doi: 10.1002/pros.24249.
    PubMed     Abstract available

  226. IKEUCHI W, Wakita Y, Zhang G, Li C, et al
    AT-rich interaction domain 5A regulates the transcription of interleukin-6 gene in prostate cancer cells.
    Prostate. 2021 Oct 11. doi: 10.1002/pros.24251.
    PubMed     Abstract available

  227. JIMBO M, Andrews JR, Ahmed ME, Dundar A, et al
    Prognostic role of 11C-choline PET/CT scan in patients with metastatic castrate resistant prostate cancer undergoing primary docetaxel chemotherapy.
    Prostate. 2021 Oct 11. doi: 10.1002/pros.24246.
    PubMed     Abstract available

  228. PREBAY ZJ, Medairos R, Doolittle J, Langenstroer P, et al
    The prognostic value of digital rectal exam for the existence of advanced pathologic features after prostatectomy.
    Prostate. 2021;81:1064-1070.
    PubMed     Abstract available

    September 2021
  229. YIN Y, Liu Q, Shao Y, He X, et al
    Regulatory mechanism of androgen receptor on NCAPD3 gene expression in prostate cancer.
    Prostate. 2021 Sep 30. doi: 10.1002/pros.24245.
    PubMed     Abstract available

  230. YU C, Niu L, Li L, Li T, et al
    Identification of the metabolic signatures of prostate cancer by mass spectrometry-based plasma and urine metabolomics analysis.
    Prostate. 2021 Sep 30. doi: 10.1002/pros.24229.
    PubMed     Abstract available

  231. YANAGISAWA T, Kimura T, Mori K, Suzuki H, et al
    Abiraterone acetate versus nonsteroidal antiandrogen with androgen deprivation therapy for high-risk metastatic hormone-sensitive prostate cancer.
    Prostate. 2021 Sep 24. doi: 10.1002/pros.24243.
    PubMed     Abstract available

  232. YONEYAMA T, Yamamoto H, Sutoh Yoneyama M, Tobisawa Y, et al
    Characteristics of alpha2,3-sialyl N-glycosylated PSA as a biomarker for clinically significant prostate cancer in men with elevated PSA level.
    Prostate. 2021 Sep 21. doi: 10.1002/pros.24239.
    PubMed     Abstract available

  233. HERNANDEZ-LLODRA S, Segales L, Juanpere N, Marta Lorenzo T, et al
    SPOP and CHD1 alterations in prostate cancer: Relationship with PTEN loss, tumor grade, perineural infiltration, and PSA recurrence.
    Prostate. 2021 Sep 17. doi: 10.1002/pros.24218.
    PubMed     Abstract available

  234. HOEH B, Wurnschimmel C, Flammia RS, Horlemann B, et al
    Improvement in overall and cancer-specific survival in contemporary, metastatic prostate cancer chemotherapy exposed patients.
    Prostate. 2021 Sep 15. doi: 10.1002/pros.24235.
    PubMed     Abstract available

  235. JIMENEZ-ALCAIDE E, Garcia-Fuentes C, Hernandez V, De la Pena E, et al
    Influence of androgen deprivation therapy on the severity of COVID-19 in prostate cancer patients.
    Prostate. 2021 Sep 13. doi: 10.1002/pros.24232.
    PubMed     Abstract available

  236. LETHONGSAVARN V, Pinault M, Diedhiou A, Guimaraes C, et al
    Tissue cholesterol metabolism and prostate cancer aggressiveness: Ethno-geographic variations.
    Prostate. 2021 Sep 13. doi: 10.1002/pros.24234.
    PubMed     Abstract available

  237. AYDOS U, Cetin S, Akdemir UO, Budak FC, et al
    The role of histopathological and biochemical parameters for predicting metastatic disease on (68) Ga-PSMA-11 PET in prostate cancer.
    Prostate. 2021 Sep 13. doi: 10.1002/pros.24231.
    PubMed     Abstract available

  238. WATANABE R, Maekawa M, Kiyoi T, Kurata M, et al
    PSMA-positive membranes secreted from prostate cancer cells have potency to transform vascular endothelial cells into an angiogenic state.
    Prostate. 2021 Sep 13. doi: 10.1002/pros.24237.
    PubMed     Abstract available

  239. LIU Y, Dong Y, Liu J, Zhang X, et al
    Comparison between (18) F-DCFPyL PET and MRI for the detection of transition zone prostate cancer.
    Prostate. 2021 Sep 13. doi: 10.1002/pros.24230.
    PubMed     Abstract available

  240. CHHATRE S, Malkowicz SB, Jayadevappa R
    Continuity of care in acute survivorship phase, and short and long-term outcomes in prostate cancer patients.
    Prostate. 2021 Sep 13. doi: 10.1002/pros.24228.
    PubMed     Abstract available

  241. SOKOLOVA AO, Marshall CH, Lozano R, Gulati R, et al
    Efficacy of systemic therapies in men with metastatic castration resistant prostate cancer harboring germline ATM versus BRCA2 mutations.
    Prostate. 2021 Sep 13. doi: 10.1002/pros.24236.
    PubMed     Abstract available

  242. CHO MC, Yoo S, Choo MS, Son H, et al
    Lymphocyte-to-monocyte ratio is a predictor of clinically significant prostate cancer at prostate biopsy.
    Prostate. 2021 Sep 13. doi: 10.1002/pros.24222.
    PubMed     Abstract available

  243. MANGOSH TL, Grabowska MM, Taylor DJ
    SLX4IP N-terminus dictates telomeric localization in ALT-like castration-resistant prostate cancer cell lines.
    Prostate. 2021 Sep 7. doi: 10.1002/pros.24225.
    PubMed     Abstract available

  244. MATSUDA T, Miyata Y, Nakamura Y, Otsubo A, et al
    Pathological significance and prognostic role of LATS2 in prostate cancer.
    Prostate. 2021 Sep 7. doi: 10.1002/pros.24226.
    PubMed     Abstract available

  245. MIYAHIRA AK, Soule HR
    The 27th Annual Prostate Cancer Foundation Scientific Retreat Report.
    Prostate. 2021 Sep 1. doi: 10.1002/pros.24211.
    PubMed     Abstract available

  246. SUMAN S, Parghane RV, Joshi A, Prabhash K, et al
    Combined (177) Lu-PSMA-617 PRLT and abiraterone acetate versus (177) Lu-PSMA-617 PRLT monotherapy in metastatic castration-resistant prostate cancer: An observational study comparing the response and durability.
    Prostate. 2021 Sep 1. doi: 10.1002/pros.24219.
    PubMed     Abstract available

  247. EKSI M, Evren I, Akkas F, Arikan Y, et al
    Machine learning algorithms can more efficiently predict biochemical recurrence after robot-assisted radical prostatectomy.
    Prostate. 2021;81:913-920.
    PubMed     Abstract available

  248. IAKYMENKO OA, Lugo I, Briski LM, Nemov I, et al
    Percentage of Gleason pattern 4 and tumor volume predict adverse pathological stage and margin status at radical prostatectomy in grade Group 2 and grade Group 3 prostate cancers.
    Prostate. 2021;81:866-873.
    PubMed     Abstract available

  249. MARTINEZ O, Murphy C, Bsatee A, Abaza R, et al
    Impact of median lobe on urinary function after robotic prostatectomy.
    Prostate. 2021;81:832-837.
    PubMed     Abstract available

  250. LONERGAN PE, Cowan JE, Washington SL 3rd, Greenberg SA, et al
    Natural history of an immediately detectable PSA following radical prostatectomy in a contemporary cohort.
    Prostate. 2021;81:1009-1017.
    PubMed     Abstract available

  251. SANCHES BDA, Maldarine JS, Vilamaior PSL, Felisbino SL, et al
    Stromal cell interplay in prostate development, physiology, and pathological conditions.
    Prostate. 2021;81:926-937.
    PubMed     Abstract available

  252. WEE CE, Costello BA, Orme JJ, Quevedo JF, et al
    Chemotherapy with atezolizumab for small cell or neuroendocrine carcinoma of the prostate: A single institution experience.
    Prostate. 2021;81:938-943.
    PubMed     Abstract available

    August 2021
  253. LEDET EM, Sartor O
    Letter to the Editor: "Family history and pathogenic/likely pathogenic germline variants in prostate cancer patients".
    Prostate. 2021 Aug 31. doi: 10.1002/pros.24221.

  254. DI MAIDA F, Grosso AA, Minervini A
    Letter to the Editor: "Family history and pathogenic/likely pathogenic germline variants in prostate cancer patients".
    Prostate. 2021 Aug 31. doi: 10.1002/pros.24220.

  255. SHAO L, Wang J, Karatas O, Ittmann M, et al
    MEX3D is an oncogenic driver in prostate cancer.
    Prostate. 2021 Aug 29. doi: 10.1002/pros.24216.
    PubMed     Abstract available

  256. SUN BL
    Immunotherapy in treatment of metastatic prostate cancer: An approach to circumvent immunosuppressive tumor microenvironment.
    Prostate. 2021 Aug 26. doi: 10.1002/pros.24213.
    PubMed     Abstract available

  257. WANG Z, Zhu S, Zhao J, Nie L, et al
    The heterogeneity of intraductal carcinoma of the prostate is associated with different efficacy of standard first-line therapy for patients with metastatic castration-resistant prostate cancer.
    Prostate. 2021 Aug 26. doi: 10.1002/pros.24215.
    PubMed     Abstract available

  258. OKINAKA Y, Kageyama S, Nishizawa K, Yoshida T, et al
    Clinical, pathological, and therapeutic features of newly diagnosed prostate cancer predominantly detected by opportunistic PSA screening: A survey of Shiga Prefecture, Japan.
    Prostate. 2021 Aug 21. doi: 10.1002/pros.24212.
    PubMed     Abstract available

  259. HAFFNER MC, Bhamidipati A, Tsai HK, Esopi DM, et al
    Phenotypic characterization of two novel cell line models of castration-resistant prostate cancer.
    Prostate. 2021 Aug 16. doi: 10.1002/pros.24210.
    PubMed     Abstract available

  260. WENZEL M, Wurnschimmel C, Nocera L, Ruvolo CC, et al
    The effect of primary urological cancers on survival in men with secondary prostate cancer.
    Prostate. 2021 Aug 16. doi: 10.1002/pros.24209.
    PubMed     Abstract available

  261. NANDALUR KR, Colvin R, Walker D, Nandalur SR, et al
    Benign prostate hyperplasia as a potential protective factor against prostate cancer: Insights from a magnetic resonance imaging study of compositional characteristics.
    Prostate. 2021 Aug 10. doi: 10.1002/pros.24207.
    PubMed     Abstract available

  262. WURNSCHIMMEL C, Wenzel M, Wang N, Tian Z, et al
    Long-term overall survival of radical prostatectomy patients is often superior to the general population: A comparison using life-table data.
    Prostate. 2021;81:785-793.
    PubMed     Abstract available

  263. WURNSCHIMMEL C, Wenzel M, Chierigo F, Flammia RS, et al
    Presence of biopsy Gleason pattern 5 + 3 is associated with higher mortality after radical prostatectomy but not after external beam radiotherapy compared to other Gleason Grade Group IV patterns.
    Prostate. 2021;81:778-784.
    PubMed     Abstract available

  264. WAGASKAR VG, Ratnani P, Levy M, Moody K, et al
    Clinical characteristics and oncological outcomes in negative multiparametric MRI patients undergoing robot-assisted radical prostatectomy.
    Prostate. 2021;81:772-777.
    PubMed     Abstract available

    July 2021
  265. ROSSIGNOL T, Gourtaud G, Senechal C, Sadreux Y, et al
    Characteristics and progression-free survival of Afro-Caribbean men with metastatic hormone-sensitive prostate cancer at the time of diagnosis.
    Prostate. 2021 Jul 28. doi: 10.1002/pros.24206.
    PubMed     Abstract available

  266. LEIS-FILHO AF, Lainetti PD, Kobayashi PE, Palmieri C, et al
    Expression and prognostic significance of vascular endothelial growth factor-A (VEGF-A) and its receptor in canine prostate cancer.
    Prostate. 2021 Jul 28. doi: 10.1002/pros.24199.
    PubMed     Abstract available

  267. CAO Y, Zhang W, Li Y, Fu J, et al
    Rates and trends in stage-specific prostate cancer incidence by age and race/ethnicity, 2000-2017.
    Prostate. 2021 Jul 28. doi: 10.1002/pros.24204.
    PubMed     Abstract available

  268. WENZEL M, Wurnschimmel C, Chierigo F, Tian Z, et al
    Assessment of the optimal number of positive biopsy cores to discriminate between cancer-specific mortality in high-risk versus very high-risk prostate cancer patients.
    Prostate. 2021 Jul 26. doi: 10.1002/pros.24202.
    PubMed     Abstract available

  269. CHAO OS, Goodman OB Jr
    DNA-PKc inhibition overcomes taxane resistance by promoting taxane-induced DNA damage in prostate cancer cells.
    Prostate. 2021 Jul 23. doi: 10.1002/pros.24200.
    PubMed     Abstract available

    Very low-risk versus low-risk prostate cancer: A distinction worth keeping.
    Prostate. 2021 Jul 12. doi: 10.1002/pros.24197.

  271. WEI J, Yang W, Shi Z, Lu L, et al
    Observed evidence for guideline-recommended genes in predicting prostate cancer risk from a large population-based cohort.
    Prostate. 2021 Jul 12. doi: 10.1002/pros.24195.
    PubMed     Abstract available

  272. FETTKE H, Kwan EM, Bukczynska P, Steen JA, et al
    Independent prognostic impact of plasma NCOA2 alterations in metastatic castration-resistant prostate cancer.
    Prostate. 2021 Jul 12. doi: 10.1002/pros.24194.
    PubMed     Abstract available

  273. LIU G, Zhu Y, Yao Z, Jiang Y, et al
    Development and validation of a predictive model for determining clinically significant prostate cancer in men with negative magnetic resonance imaging after transrectal ultrasound-guided prostate biopsy.
    Prostate. 2021 Jul 12. doi: 10.1002/pros.24193.
    PubMed     Abstract available

  274. HUANG D, Ruan X, Wu Y, Lin X, et al
    Genetic polymorphisms at 19q13.33 are associated with [-2]proPSA (p2PSA) levels and provide additional predictive value to prostate health index for prostate cancer.
    Prostate. 2021 Jul 12. doi: 10.1002/pros.24192.
    PubMed     Abstract available

  275. LAUNER BM, Lloyd GL
    Sociodemographic index and global trends in prostate cancer: 1990-2017.
    Prostate. 2021 Jul 5. doi: 10.1002/pros.24178.
    PubMed     Abstract available

  276. CHEN DY, Su PJ, See LC, Liu JR, et al
    Gonadotropin-releasing hormone antagonist associated with lower cardiovascular risk compared with gonadotropin-releasing hormone agonist in prostate cancer: A nationwide cohort and in vitro study.
    Prostate. 2021 Jul 1. doi: 10.1002/pros.24187.
    PubMed     Abstract available

  277. BROGGI G, Lo Giudice A, Di Mauro M, Asmundo MG, et al
    SRSF-1 and microvessel density immunohistochemical analysis by semi-automated tissue microarray in prostate cancer patients with diabetes (DIAMOND study).
    Prostate. 2021 Jul 1. doi: 10.1002/pros.24185.
    PubMed     Abstract available

  278. CORRADI JP, Cumarasamy CW, Staff I, Tortora J, et al
    Identification of a five gene signature to predict time to biochemical recurrence after radical prostatectomy.
    Prostate. 2021;81:694-702.
    PubMed     Abstract available

    June 2021
  279. LV S, Pu X, Luo M, Wen H, et al
    Long noncoding RNA GAS5 interacts and suppresses androgen receptor activity in prostate cancer cells.
    Prostate. 2021 Jun 29. doi: 10.1002/pros.24186.
    PubMed     Abstract available

  280. WENZEL M, Wurnschimmel C, Ruvolo CC, Nocera L, et al
    Increasing rates of NCCN high and very high-risk prostate cancer versus number of prostate biopsy cores.
    Prostate. 2021 Jun 29. doi: 10.1002/pros.24184.
    PubMed     Abstract available

  281. LENDINEZ-CANO G, Ojeda-Claro AV, Gomez-Gomez E, Morales Jimenez P, et al
    Prospective study of diagnostic accuracy in the detection of high-grade prostate cancer in biopsy-naive patients with clinical suspicion of prostate cancer who underwent the Select MDx test.
    Prostate. 2021 Jun 29. doi: 10.1002/pros.24182.
    PubMed     Abstract available

  282. BASU HS, Wilganowski N, Robertson S, Reuben JM, et al
    Prostate cancer cells survive anti-androgen and mitochondrial metabolic inhibitors by modulating glycolysis and mitochondrial metabolic activities.
    Prostate. 2021 Jun 25. doi: 10.1002/pros.24146.
    PubMed     Abstract available

  283. NUNES-XAVIER CE, Kildal W, Kleppe A, Danielsen HE, et al
    Immune checkpoint B7-H3 protein expression is associated with poor outcome and androgen receptor status in prostate cancer.
    Prostate. 2021 Jun 14. doi: 10.1002/pros.24180.
    PubMed     Abstract available

  284. WURNSCHIMMEL C, Kachanov M, Wenzel M, Mandel P, et al
    Twenty-year trends in prostate cancer stage and grade migration in a large contemporary german radical prostatectomy cohort.
    Prostate. 2021 Jun 10. doi: 10.1002/pros.24181.
    PubMed     Abstract available

  285. FALEGAN OS, Jarvi K, Vogel HJ, Hyndman ME, et al
    Seminal plasma metabolomics reveals lysine and serine dysregulation as unique features distinguishing between prostate cancer tumors of Gleason grades 6 and 7.
    Prostate. 2021 Jun 7. doi: 10.1002/pros.24145.
    PubMed     Abstract available

  286. WANG L, Li H, Li Z, Li M, et al
    Smoothened loss is a characteristic of neuroendocrine prostate cancer.
    Prostate. 2021;81:508-520.
    PubMed     Abstract available

  287. NIZIALEK E, Lim SJ, Wang H, Isaacsson Velho P, et al
    Genomic profiles and clinical outcomes in primary versus secondary metastatic hormone-sensitive prostate cancer.
    Prostate. 2021;81:572-579.
    PubMed     Abstract available

  288. WESTHOFEN T, Buchner A, Schlenker B, Becker A, et al
    A matter of size? Health-related quality of life after radical prostatectomy for patients with giant prostates.
    Prostate. 2021;81:443-451.
    PubMed     Abstract available

  289. CIPOLLARI S, Jamshidi N, Du L, Sung K, et al
    Tissue clearing techniques for three-dimensional optical imaging of intact human prostate and correlations with multi-parametric MRI.
    Prostate. 2021;81:521-529.
    PubMed     Abstract available

  290. XIAO GQ, Ho G, Suen C, Hurth KM, et al
    Comparative study of neuroendocrine acquisition and biomarker expression between neuroendocrine and usual prostatic carcinoma.
    Prostate. 2021;81:469-477.
    PubMed     Abstract available

    May 2021
  291. LOEB S, Li R, Sanchez Nolasco T, Byrne N, et al
    Barriers and facilitators of germline genetic evaluation for prostate cancer.
    Prostate. 2021 May 31. doi: 10.1002/pros.24172.
    PubMed     Abstract available

  292. QUHAL F, Rajwa P, Mori K, Laukhtina E, et al
    The role of lymph node dissection in salvage radical prostatectomy for patients with radiation recurrent prostate cancer.
    Prostate. 2021 May 31. doi: 10.1002/pros.24173.
    PubMed     Abstract available

  293. SI S, Zheng B, Wang Z, Niu Z, et al
    Does surgery benefit patients with oligometastatic or metastatic prostate cancer? - A retrospective cohort study and meta-analysis.
    Prostate. 2021 May 31. doi: 10.1002/pros.24170.
    PubMed     Abstract available

  294. MISHRA A, Zennami K, Velarde E, Thorek DLJ, et al
    Longitudinal measurement of subcutaneous and intratibial human prostate cancer xenograft growth and response to ionizing radiation by plasma Alu and LINE-1 ctDNA: A comparison to standard methods.
    Prostate. 2021 May 25. doi: 10.1002/pros.24171.
    PubMed     Abstract available

  295. ZHU S, Chen J, Ni Y, Zhang H, et al
    Dynamic multidisciplinary team discussions can improve the prognosis of metastatic castration-resistant prostate cancer patients.
    Prostate. 2021 May 24. doi: 10.1002/pros.24167.
    PubMed     Abstract available

  296. WENZEL M, Wurnschimmel C, Chierigo F, Tian Z, et al
    Non-cancer mortality in elderly prostate cancer patients treated with combination of radical prostatectomy and external beam radiation therapy.
    Prostate. 2021 May 19. doi: 10.1002/pros.24169.
    PubMed     Abstract available

  297. FERRARIS F, Yaber F, Smith AB, Barreiro D, et al
    The end of "very low risk" in localized prostate cancer?
    Prostate. 2021 May 19. doi: 10.1002/pros.24168.

  298. SARTOR O, Appukkuttan S, Weiss J, Tsao CK, et al
    Clinical outcomes, management, and treatment patterns in patients with metastatic castration-resistant prostate cancer treated with radium-223 in community compared to academic settings.
    Prostate. 2021 May 12. doi: 10.1002/pros.24143.
    PubMed     Abstract available

  299. XU J, Isaacs WB, Mamawala M, Shi Z, et al
    Association of prostate cancer polygenic risk score with number and laterality of tumor cores in active surveillance patients.
    Prostate. 2021 May 6. doi: 10.1002/pros.24140.
    PubMed     Abstract available

  300. BANERJEE M, Li Z, Gao Y, Lai F, et al
    Inverse agonism at the Na/K-ATPase receptor reverses EMT in prostate cancer cells.
    Prostate. 2021 May 6. doi: 10.1002/pros.24144.
    PubMed     Abstract available

  301. WANG V, Geybels MS, Jordahl KM, Gerke T, et al
    A polymorphism in the promoter of FRAS1 is a candidate SNP associated with metastatic prostate cancer.
    Prostate. 2021 May 6. doi: 10.1002/pros.24148.
    PubMed     Abstract available

  302. DE GROOT AE, Myers KV, Krueger TEG, Kiemen AL, et al
    Characterization of tumor-associated macrophages in prostate cancer transgenic mouse models.
    Prostate. 2021 May 5. doi: 10.1002/pros.24139.
    PubMed     Abstract available

  303. CHI JT, Lin PH, Tolstikov V, Oyekunle T, et al
    The influence of low-carbohydrate diets on the metabolic response to androgen-deprivation therapy in prostate cancer.
    Prostate. 2021 May 5. doi: 10.1002/pros.24136.
    PubMed     Abstract available

  304. ONAL C, Ozyigit G, Oymak E, Guler OC, et al
    Clinical parameters and nomograms for predicting lymph node metastasis detected with (68) Ga-PSMA-PET/CT in prostate cancer patients candidate to definitive radiotherapy.
    Prostate. 2021 May 5. doi: 10.1002/pros.24142.
    PubMed     Abstract available

  305. WENZEL M, Wurnschimmel C, Nocera L, Colla Ruvolo C, et al
    The effect of lymph node dissection on cancer-specific survival in salvage radical prostatectomy patients.
    Prostate. 2021;81:339-346.
    PubMed     Abstract available

  306. LEON P, Cancel-Tassin G, Bourdon V, Buecher B, et al
    Bayesian predictive model to assess BRCA2 mutational status according to clinical history: Early onset, metastatic phenotype or family history of breast/ovary cancer.
    Prostate. 2021;81:318-325.
    PubMed     Abstract available

  307. ZHAO H, Howard LE, De Hoedt AM, Terris MK, et al
    Safety of concomitant therapy with radium-223 and abiraterone or enzalutamide in a real-world population.
    Prostate. 2021;81:390-397.
    PubMed     Abstract available

    April 2021
  308. TAN B, Chen X, Fan Y, Yang Y, et al
    STAT3 phosphorylation is required for the HepaCAM-mediated inhibition of castration-resistant prostate cancer cell viability and metastasis.
    Prostate. 2021 Apr 28. doi: 10.1002/pros.24141.
    PubMed     Abstract available

  309. BALLAL S, Yadav MP, Sahoo RK, Tripathi M, et al
    (225) Ac-PSMA-617-targeted alpha therapy for the treatment of metastatic castration-resistant prostate cancer: A systematic review and meta-analysis.
    Prostate. 2021 Apr 27. doi: 10.1002/pros.24137.
    PubMed     Abstract available

  310. QU F, Gu Y, Xue M, He M, et al
    Impact of therapy on cancer metabolism in high-risk localized prostate cancer treated with neoadjuvant docetaxel and androgen deprivation therapy.
    Prostate. 2021 Apr 27. doi: 10.1002/pros.24134.
    PubMed     Abstract available

  311. HISHIDA S, Kawakami K, Fujita Y, Kato T, et al
    Proteomic analysis of extracellular vesicles identified PI3K pathway as a potential therapeutic target for cabazitaxel-resistant prostate cancer.
    Prostate. 2021 Apr 27. doi: 10.1002/pros.24138.
    PubMed     Abstract available

  312. BOSLAND MC, Nettey OS, Phillips AA, Anunobi CC, et al
    Prevalence of prostate cancer at autopsy in Nigeria-A preliminary report.
    Prostate. 2021 Apr 27. doi: 10.1002/pros.24133.
    PubMed     Abstract available

  313. ONAL C, Kose F, Ozyigit G, Aksoy S, et al
    Stereotactic body radiotherapy for oligoprogressive lesions in metastatic castration-resistant prostate cancer patients during abiraterone/enzalutamide treatment.
    Prostate. 2021 Apr 27. doi: 10.1002/pros.24132.
    PubMed     Abstract available

  314. BAZZI LA, Sigurdardottir LG, Sigurdsson S, Valdimarsdottir U, et al
    Exploratory assessment of pineal gland volume, composition, and urinary 6-sulfatoxymelatonin levels on prostate cancer risk.
    Prostate. 2021 Apr 16. doi: 10.1002/pros.24130.
    PubMed     Abstract available

  315. THULIN MH, Maatta J, Linder A, Sterbova S, et al
    Inhibition of STAT3 prevents bone metastatic progression of prostate cancer in vivo.
    Prostate. 2021 Apr 6. doi: 10.1002/pros.24125.
    PubMed     Abstract available

  316. WANG Y, Wu G, Fan L, Pan J, et al
    The prognostic nomogram including MRI for locally advanced prostate cancer treated by radical prostatectomy.
    Prostate. 2021 Apr 6. doi: 10.1002/pros.24126.
    PubMed     Abstract available

    March 2021
  317. SWANSON GP, Lenz L, Stone S, Cohen T, et al
    Cell-cycle risk score more accurately determines the risk for metastases and death in prostatectomy patients compared with clinical features alone.
    Prostate. 2021;81:261-267.
    PubMed     Abstract available

  318. TAN YG, Khalid F, Huang HH, Chen K, et al
    Prostatic ductal adenocarcinoma variant predicts worse pathological and oncological outcomes: Insight from over 1000 consecutive patients from a large prospective uro-oncology registry.
    Prostate. 2021;81:242-251.
    PubMed     Abstract available

  319. LI Y, Ge C, Franceschi RT
    Role of Runx2 in prostate development and stem cell function.
    Prostate. 2021;81:231-241.
    PubMed     Abstract available

    February 2021
  320. LEE JM, Kim U, Yang H, Ryu B, et al
    TALEN-mediated generation of Nkx3.1 knockout rat model.
    Prostate. 2021;81:182-193.
    PubMed     Abstract available

    January 2021
  321. ZHU Y, Wen J, Huang G, Mittlesteadt J, et al
    CHD1 and SPOP synergistically protect prostate epithelial cells from DNA damage.
    Prostate. 2021;81:81-88.
    PubMed     Abstract available

Thank you for your interest in scientific medicine.

AMEDEO Prostate Cancer is free of charge.
This policy is made possible thanks to a media sponsorship by Boehringer Ingelheim.